Literature DB >> 33420618

A 2-year longitudinal study of bone health in adolescent patients with axial spondyloarthritis.

Shin-Hee Kim1, Ki Hwan Kim1, Moon-Young Kim2, Yeon Sik Hong2, Kwi Young Kang3.   

Abstract

PURPOSE: Axial spondyloarthritis (axSpA) is a chronic inflammatory disease that primarily affects the axial skeleton and typically has an early onset. Although earlier onset is associated with worse prognosis, there have been few studies of bone mineral density (BMD) in adolescent patients with axSpA.
METHODS: We analysed the clinical characteristics of 43 adolescent patients with axSpA at a baseline assessment and at a follow-up 2 years later. The baseline assessment included age, disease duration, treatment agents, and clinical, radiologic, and laboratory data. BMD of the lumbar spine, femoral neck, and total hip were measured by dual-energy X-ray absorptiometry during both the baseline assessment and the 2-year follow-up. We performed multivariate linear regression analyses to identify factors independently associated with BMD. We analysed the associations between changes in BMD and reductions in inflammatory markers.
RESULTS: The average age of participants was 17.9 years and the mean disease duration was 2.2 years. Of the 43 patients, 10 (23%) had low BMD at any site (lumbar spine, femoral neck, and/or total hip). At baseline, multivariate analysis showed that body mass index (BMI), erythrocyte sedimentation rate (ESR), and spinal structural damage were associated with lumbar spine Z-scores. Increases in BMD in the lumbar spine were correlated with reductions in ESR (r = 0.40, P = 0.02) and C-reactive protein (CRP) (r = 0.40, P = 0.02). Increases in BMD in the total hip were correlated with reductions in CRP (r = 0.38, P = 0.03).
CONCLUSION: In adolescent axSpA patients, bone health was associated with systemic inflammation and the severity of structural damage. Reduced systemic inflammation was associated with improvements in bone health.

Entities:  

Keywords:  Adolescent; Axial spondyloarthritis; Bone health

Mesh:

Year:  2021        PMID: 33420618     DOI: 10.1007/s11657-020-00860-y

Source DB:  PubMed          Journal:  Arch Osteoporos            Impact factor:   2.617


  5 in total

1.  International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001.

Authors:  Ross E Petty; Taunton R Southwood; Prudence Manners; John Baum; David N Glass; Jose Goldenberg; Xiaohu He; Jose Maldonado-Cocco; Javier Orozco-Alcala; Anne-Marie Prieur; Maria E Suarez-Almazor; Patricia Woo
Journal:  J Rheumatol       Date:  2004-02       Impact factor: 4.666

2.  Biochemical markers of bone metabolism in mild ankylosing spondylitis and their relationship with bone mineral density and vertebral fractures.

Authors:  D Mitra; D M Elvins; A J Collins
Journal:  J Rheumatol       Date:  1999-10       Impact factor: 4.666

3.  A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index.

Authors:  A Calin; S Garrett; H Whitelock; L G Kennedy; J O'Hea; P Mallorie; T Jenkinson
Journal:  J Rheumatol       Date:  1994-12       Impact factor: 4.666

4.  A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index.

Authors:  S Garrett; T Jenkinson; L G Kennedy; H Whitelock; P Gaisford; A Calin
Journal:  J Rheumatol       Date:  1994-12       Impact factor: 4.666

5.  Evaluation of bone mass in children and young adults with juvenile idiopathic arthritis.

Authors:  Tingting Tang; Xuemei Tang; Li Xu; Yingbo Huang; Jie Zeng; Qiu Li
Journal:  Clin Exp Rheumatol       Date:  2015-07-23       Impact factor: 4.473

  5 in total
  1 in total

1.  The Relationship Between Prediabetes and Bone Mass in Adolescents: Analysis of the National Health and Nutrition Examination Survey From 2005 to 2010.

Authors:  Chun-Ming Ma; Fu-Zai Yin
Journal:  Front Endocrinol (Lausanne)       Date:  2021-10-25       Impact factor: 5.555

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.